Do analysts recommend XBIT or ANIK?

Anika Therapeutics has a consensus price target of $21.00, indicating a potential upside of 0.00%. Given Anika Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Anika Therapeutics is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Anika Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Does the media refer more to XBIT or ANIK?

In the previous week, Anika Therapeutics had 1 more articles in the media than XBiotech. MarketBeat recorded 3 mentions for Anika Therapeutics and 2 mentions for XBiotech. Anika Therapeutics' average media sentiment score of 1.73 beat XBiotech's score of 0.58 indicating that Anika Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XBiotech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anika Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer XBIT or TRDA?

Entrada Therapeutics has a consensus target price of $17.75, indicating a potential upside of 147.56%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Entrada Therapeutics is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Entrada Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media prefer XBIT or TRDA?

In the previous week, Entrada Therapeutics had 14 more articles in the media than XBiotech. MarketBeat recorded 16 mentions for Entrada Therapeutics and 2 mentions for XBiotech. Entrada Therapeutics' average media sentiment score of 0.67 beat XBiotech's score of 0.58 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XBiotech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entrada Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer XBIT or SION?

Sionna Therapeutics has a consensus target price of $42.22, indicating a potential upside of 525.51%. Given Sionna Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sionna Therapeutics is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sionna Therapeutics 1 Sell rating(s) 11 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, XBIT or SION?

Sionna Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XBiotech N/A N/A -$45.54M -$1.48 N/A Sionna Therapeutics N/A N/A -$75.27M -$2.18 N/A

Is XBIT or SION more profitable?

XBiotech's return on equity of -31.62% beat Sionna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets XBiotech N/A -31.62% -30.29% Sionna Therapeutics N/A -32.94% -31.08%

Does the media refer more to XBIT or SION?

In the previous week, Sionna Therapeutics had 4 more articles in the media than XBiotech. MarketBeat recorded 6 mentions for Sionna Therapeutics and 2 mentions for XBiotech. XBiotech's average media sentiment score of 0.58 beat Sionna Therapeutics' score of 0.23 indicating that XBiotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XBiotech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sionna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend XBIT or PYXS?

Pyxis Oncology has a consensus price target of $7.50, indicating a potential upside of 110.08%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pyxis Oncology 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70

Is XBIT or PYXS more profitable?

XBiotech's return on equity of -31.62% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets XBiotech N/A -31.62% -30.29% Pyxis Oncology N/A -215.23% -112.19%

Does the media refer more to XBIT or PYXS?

In the previous week, XBiotech had 1 more articles in the media than Pyxis Oncology. MarketBeat recorded 2 mentions for XBiotech and 1 mentions for Pyxis Oncology. XBiotech's average media sentiment score of 0.58 beat Pyxis Oncology's score of 0.00 indicating that XBiotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XBiotech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pyxis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate XBIT or ACIU?

AC Immune has a consensus target price of $7.50, suggesting a potential upside of 155.97%. Given AC Immune's stronger consensus rating and higher possible upside, analysts clearly believe AC Immune is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AC Immune 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is XBIT or ACIU more profitable?

XBiotech has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. XBiotech's return on equity of -31.62% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets XBiotech N/A -31.62% -30.29% AC Immune -245.32% -100.17% -28.36%

Does the media refer more to XBIT or ACIU?

In the previous week, XBiotech and XBiotech both had 2 articles in the media. AC Immune's average media sentiment score of 1.25 beat XBiotech's score of 0.58 indicating that AC Immune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XBiotech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AC Immune 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

XBiotech (XBIT) Competitors

$2.20 +0.01 (+0.46%)

As of 09/3/2026 04:00 PM Eastern

Compare

XBIT vs. ANIK, TRDA, SION, PYXS, and ACIU

Should you buy XBiotech stock or one of its competitors? XBiotech's main competitors and comparable companies include Anika Therapeutics (ANIK), Entrada Therapeutics (TRDA), Sionna Therapeutics (SION), Pyxis Oncology (PYXS), and AC Immune (ACIU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does XBiotech compare to Anika Therapeutics?

XBiotech (NASDAQ:XBIT) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

XBiotech has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat XBiotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-31.62%	-30.29%
Anika Therapeutics	-3.14%	0.20%	0.15%

Anika Therapeutics has higher revenue and earnings than XBiotech. Anika Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A
Anika Therapeutics	$112.82M	2.49	-$10.88M	-$0.27	N/A

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 30.8% of XBiotech shares are owned by company insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Anika Therapeutics had 1 more articles in the media than XBiotech. MarketBeat recorded 3 mentions for Anika Therapeutics and 2 mentions for XBiotech. Anika Therapeutics' average media sentiment score of 1.73 beat XBiotech's score of 0.58 indicating that Anika Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XBiotech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anika Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Anika Therapeutics has a consensus price target of $21.00, indicating a potential upside of 0.00%. Given Anika Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Anika Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

XBiotech has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Summary

Anika Therapeutics beats XBiotech on 12 of the 16 factors compared between the two stocks.

How does XBiotech compare to Entrada Therapeutics?

XBiotech (NASDAQ:XBIT) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

XBiotech has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -3,537.73%. XBiotech's return on equity of -31.62% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-31.62%	-30.29%
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 30.8% of XBiotech shares are owned by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

XBiotech has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market.

In the previous week, Entrada Therapeutics had 14 more articles in the media than XBiotech. MarketBeat recorded 16 mentions for Entrada Therapeutics and 2 mentions for XBiotech. Entrada Therapeutics' average media sentiment score of 0.67 beat XBiotech's score of 0.58 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XBiotech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entrada Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Entrada Therapeutics has a consensus target price of $17.75, indicating a potential upside of 147.56%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Entrada Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

XBiotech has higher earnings, but lower revenue than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A
Entrada Therapeutics	$25.42M	10.98	-$143.75M	-$3.96	N/A

Summary

XBiotech beats Entrada Therapeutics on 8 of the 15 factors compared between the two stocks.

How does XBiotech compare to Sionna Therapeutics?

XBiotech (NASDAQ:XBIT) and Sionna Therapeutics (NASDAQ:SION) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Sionna Therapeutics has a consensus target price of $42.22, indicating a potential upside of 525.51%. Given Sionna Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sionna Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sionna Therapeutics	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sionna Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A

In the previous week, Sionna Therapeutics had 4 more articles in the media than XBiotech. MarketBeat recorded 6 mentions for Sionna Therapeutics and 2 mentions for XBiotech. XBiotech's average media sentiment score of 0.58 beat Sionna Therapeutics' score of 0.23 indicating that XBiotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XBiotech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sionna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

55.7% of XBiotech shares are held by institutional investors. 30.8% of XBiotech shares are held by company insiders. Comparatively, 5.1% of Sionna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

XBiotech has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

XBiotech's return on equity of -31.62% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-31.62%	-30.29%
Sionna Therapeutics	N/A	-32.94%	-31.08%

Summary

XBiotech beats Sionna Therapeutics on 8 of the 13 factors compared between the two stocks.

How does XBiotech compare to Pyxis Oncology?

XBiotech (NASDAQ:XBIT) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

55.7% of XBiotech shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 30.8% of XBiotech shares are held by insiders. Comparatively, 5.7% of Pyxis Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, XBiotech had 1 more articles in the media than Pyxis Oncology. MarketBeat recorded 2 mentions for XBiotech and 1 mentions for Pyxis Oncology. XBiotech's average media sentiment score of 0.58 beat Pyxis Oncology's score of 0.00 indicating that XBiotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XBiotech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pyxis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

XBiotech has higher earnings, but lower revenue than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A
Pyxis Oncology	$13.86M	21.48	-$79.62M	-$1.41	N/A

Pyxis Oncology has a consensus price target of $7.50, indicating a potential upside of 110.08%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

XBiotech has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market.

XBiotech's return on equity of -31.62% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-31.62%	-30.29%
Pyxis Oncology	N/A	-215.23%	-112.19%

Summary

XBiotech beats Pyxis Oncology on 8 of the 14 factors compared between the two stocks.

How does XBiotech compare to AC Immune?

XBiotech (NASDAQ:XBIT) and AC Immune (NASDAQ:ACIU) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 51.4% of AC Immune shares are owned by institutional investors. 30.8% of XBiotech shares are owned by company insiders. Comparatively, 4.6% of AC Immune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

AC Immune has a consensus target price of $7.50, suggesting a potential upside of 155.97%. Given AC Immune's stronger consensus rating and higher possible upside, analysts clearly believe AC Immune is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

XBiotech has higher earnings, but lower revenue than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A
AC Immune	$4.31M	69.18	-$85.03M	-$0.54	N/A

XBiotech has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. XBiotech's return on equity of -31.62% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-31.62%	-30.29%
AC Immune	-245.32%	-100.17%	-28.36%

In the previous week, XBiotech and XBiotech both had 2 articles in the media. AC Immune's average media sentiment score of 1.25 beat XBiotech's score of 0.58 indicating that AC Immune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XBiotech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AC Immune	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

XBiotech has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, AC Immune has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

Summary

AC Immune beats XBiotech on 8 of the 14 factors compared between the two stocks.

Get XBiotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XBIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XBIT vs. The Competition

Export

Metric	XBiotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$66.77M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-1.49	12.66	273.28	25.38
Price / Sales	N/A	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	0.52	16.29	12.89	6.14
Net Income	-$45.54M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-3.08%	0.34%	0.61%	-0.27%
1 Month Performance	-1.79%	8.52%	5.73%	0.68%
1 Year Performance	-26.17%	52.66%	25.37%	14.84%

XBiotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XBIT XBiotech	0.4326 of 5 stars	$2.20 +0.5%	N/A	-26.2%	$66.77M	N/A	N/A	100	News Coverage Analyst Downgrade High Trading Volume
ANIK Anika Therapeutics	3.1176 of 5 stars	$21.11 +1.1%	$21.00 -0.5%	+133.1%	$279.30M	$112.82M	N/A	300	News Coverage Positive News
TRDA Entrada Therapeutics	2.4624 of 5 stars	$7.07 +0.3%	$17.75 +151.1%	+34.8%	$274.50M	$25.42M	N/A	110	News Coverage Analyst Upgrade Insider Trade
SION Sionna Therapeutics	2.7358 of 5 stars	$6.46 +7.1%	$42.22 +553.6%	-72.5%	$272.63M	N/A	N/A	35
PYXS Pyxis Oncology	2.3886 of 5 stars	$3.44 +6.2%	$7.50 +118.0%	+142.9%	$270.24M	$13.86M	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XBIT) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XBiotech (XBIT) Competitors

XBIT vs. ANIK, TRDA, SION, PYXS, and ACIU

How does XBiotech compare to Anika Therapeutics?

Summary

How does XBiotech compare to Entrada Therapeutics?

Summary

How does XBiotech compare to Sionna Therapeutics?

Summary

How does XBiotech compare to Pyxis Oncology?

Summary

How does XBiotech compare to AC Immune?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT vs. The Competition

XBiotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XBiotech (XBIT) Competitors

XBIT vs. ANIK, TRDA, SION, PYXS, and ACIU

How does XBiotech compare to Anika Therapeutics?

Is XBIT or ANIK more profitable?

Which has stronger earnings and valuation, XBIT or ANIK?

Do institutionals & insiders have more ownership in XBIT or ANIK?

Does the media refer more to XBIT or ANIK?

Do analysts recommend XBIT or ANIK?

Which has more risk & volatility, XBIT or ANIK?

Summary

How does XBiotech compare to Entrada Therapeutics?

Is XBIT or TRDA more profitable?

Do institutionals and insiders believe in XBIT or TRDA?

Which has more volatility & risk, XBIT or TRDA?

Does the media prefer XBIT or TRDA?

Do analysts prefer XBIT or TRDA?

Which has stronger earnings & valuation, XBIT or TRDA?

Summary

How does XBiotech compare to Sionna Therapeutics?

Do analysts prefer XBIT or SION?

Which has stronger valuation and earnings, XBIT or SION?

Does the media refer more to XBIT or SION?

Do insiders & institutionals have more ownership in XBIT or SION?

Which has more risk & volatility, XBIT or SION?

Is XBIT or SION more profitable?

Summary

How does XBiotech compare to Pyxis Oncology?

Do institutionals and insiders have more ownership in XBIT or PYXS?

Does the media refer more to XBIT or PYXS?

Which has preferable earnings & valuation, XBIT or PYXS?

Do analysts recommend XBIT or PYXS?

Which has more risk and volatility, XBIT or PYXS?

Is XBIT or PYXS more profitable?

Summary

How does XBiotech compare to AC Immune?

Do insiders & institutionals hold more shares of XBIT or ACIU?

Do analysts rate XBIT or ACIU?

Which has preferable valuation & earnings, XBIT or ACIU?

Is XBIT or ACIU more profitable?

Does the media refer more to XBIT or ACIU?

Which has more risk and volatility, XBIT or ACIU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT vs. The Competition

XBiotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools